logo
NasdaqGS:QURE logo

uniQure Community

NasdaqGS:QURE Community
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 9 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

QURE logo
uniQure
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts

AMT-130 Approval Will Transform Huntington's Treatment Pipeline

Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.
View narrative
US$35.47
FV
64.3% undervalued intrinsic discount
152.22%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
4 days ago author updated this narrative